Fig. 4: Inhibition of NF-κB/EAAT3 increased ferroptosis sensitivity.
From: NF-κB-mediated EAAT3 upregulation in antioxidant defense and ferroptosis sensitivity in lung cancer
A The expression of ferroptosis marker ACSL4 and SLC7A11 in PC9 and A549 cells, respectively. B RSL3 (5 μM) treatment induced more cell death in silenced P65 or silenced EAAT3 in PC9 cells. C PI staining in PC9-siRNA-P65 and PC9-siRNA-EAAT3 cells with RSL3 treatment. D The live cell number count in siRNA-EAAT3 cells with dose-dependent RSL3 (5, 10, and 20 μM). E The live cell number count in siRNA-P65 cells with dose-dependent RSL3 (5, 10, and 20 μM). F TEM shows the morphology of mitochondria in si-EAAT3 and si-P65 PC9 cells with or without RSL3 treatment (RSL3: 5 μM). G Different ferroptosis driver genes and suppresser genes expression in PC9 cell from GSE44619. H The protein expression of ferroptosis marker GPX4, ACSL4, and SLC7A11 in cells with QNZ (5 and 10 μM) treatment. I The protein expression of ferroptosis marker GPX4 and ACSL4, the ROS marker CHAC1 in cells with QNZ (10 μM) and GSH-MEE (2 mM) treatment. *p < 0.05, **p < 0.01, error bars represent SEM.
